Drug Discovery Advisory Group
The Drug Discovery Advisory Group (DDAG) was established to provide expert scientific advice to the former Clinical and Translational Research Committee on the progress, strategy and capabilities of the drug discovery activities within the Cancer Research UK portfolio. Following Cancer Research UK's funding committee restructure, this group now provides advice to the Science Committee.
Membership of the DDAG includes scientists with substantial drug discovery expertise gained within academia and industry, in addition to expert cancer biologists - see the Committee Membership for a list of current members of the group.
The DDAG meets annually to review the annual reports of all the drug discovery activities funded by Cancer Research UK and include the following:
- The Cancer Research Technology (CRT) Discovery Laboratory - discovery projects conducted in the CRT Discovery Laboratory based at University College London and in Cambridge.
- The progress of the portfolio of projects funded by the Discovery Committee (DC) - project grants of up to two years duration and a maximum value of £0.5M.
- The Drug Discovery Programmes based in the Paterson Institute for Cancer Research, Beatson Institute for Cancer Research, Newcastle University and the Institute of Cancer Research, or the university sector, including programmes focused on:
- Small Molecule Drug Discovery at Oxford and Strathclyde universities, Imperial College London and the School of Pharmacy.
- Therapeutic Antibodies at the universities of Southampton and Oxford.
- Immunotherapy and Complex Biological Reagents at universities of Manchester, Southampton and Oxford.
Terms of reference
Other details
Contact the group secretariat for more information about the DDAG or the Cancer Research UK drug discovery programmes.
Increase text
Decrease text
Print this page